Abstract :
[en] Diabetes is a major health concern that the next-generation of on-demand insulin releasing implants may overcome via personalized therapy. Therein, 3D-printed phenylboronic acid-containing implants with on-demand glucose-triggered drug release abilities are produced using high resolution stereolithography technology. To that end, the methacrylation of phenylboronic acid is targeted following a two-step reaction. The resulting photocurable phenylboronic acid derivative is accordingly incorporated within bioinert polyhydroxyethyl methacrylate-based hydrogels at varying loadings. The end result is a sub-centimeter scaled 3D-printed bioinert implant that can be remotely activated with 1,2-diols and 1,3-diols such as glucose for on-demand drug administration such as insulin. As a proof of concept, varying glucose concentration from hypoglycemic to hyperglycemic levels readily allow the release of pinacol, i.e., a 1,2-diol-containing model molecule, at respectively low and high rates. In addition, the results demonstrated that adjusting the geometry and size of the 3D-printed part is a simple and suitable method for tailoring the release behavior and dosage.
Funding text :
We gratefully acknowledge support from both Wallonia and the European Commission \u201CFSE and FEDER\u201D. The authors acknowledge the Interreg France-Wallonie-Vlaanderen program \u201C3D4MED\u201D, with the financial support of the European Regional Development Fund (ERDF). We acknowledge the financial support from WET-T CONSOLID. O. Coulembier is Senior Research Associate at F.R.S.-FNRS of Belgium and AXA Professor of Chemistry. J.-M. Raquez is FNRS Research Director.
Scopus citations®
without self-citations
0
